# Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Source: https://onco.cc/trials/nct03334617/  
OnCo record `nct03334617` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Durvalumab, Ceralasertib, Olaparib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy is a phase 2 interventional study registered as NCT03334617 by AstraZeneca, with 528 participants enrolled, started 2017-12-18 and due to reach its primary completion in 2024-09-13. Interventions recorded: Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib. Conditions listed: Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: HUDSON
- Tags: ctgov-ingest
- Registry id: NCT03334617
- Phase: 2
- Setting: An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).
- Sponsor: AstraZeneca
- Enrolled: 528
- Outcomes: Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1): Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg 9.5% vs Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg 4.8% vs Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg 0% vs Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg 4.3% vs Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg 0% vs Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg 0% vs Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg 25.8% vs Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg 8.1% vs Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg 8.6% vs Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg vs Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg 4.3% vs Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg 0% vs Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg 4% vs Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg 21.7% vs Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg 35% vs Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg 22.7% vs Module 8 Cohort A.8.ATM: Ceralasertib 240 mg 0% vs Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg 16.7% vs Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg 8.3% vs Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg 0% vs Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg 11.8% vs Module 11 Cohort C.11.240: AZD6738 240 mg 2.6%; Overall Survival (OS): Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg 9.63 months vs Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg 5.75 months vs Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg 7.16 months vs Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg 15.51 months vs Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg 6.01 months vs Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg 11.2 months vs Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg 15.8 months vs Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg 10.22 months vs Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg 11.37 months vs Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg vs Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg 10.97 months vs Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg 7.06 months vs Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg 12.78 months vs Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg 9.53 months vs Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg 10.61 months vs Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg 14.19 months vs Module 8 Cohort A.8.ATM: Ceralasertib 240 mg 14.23 months vs Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg 7.95 months vs Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg 12.91 months vs Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg 5.95 months vs Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg 7.03 months vs Module 11 Cohort C.11.240: AZD6738 240 mg 6.6 months; Progression-Free Survival (PFS) Per RECIST v1.1: Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg 2.79 months vs Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg 1.41 months vs Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg 3.38 months vs Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg 4.17 months vs Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg 1.68 months vs Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg 3.09 months vs Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg 7.43 months vs Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg 2.96 months vs Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg 4.21 months vs Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg vs Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg 1.61 months vs Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg 1.41 months vs Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg 2.69 months vs Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg 2.83 months vs Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg 5.52 months vs Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg 4.17 months vs Module 8 Cohort A.8.ATM: Ceralasertib 240 mg 3.42 months vs Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg 1.48 months vs Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg 3.68 months vs Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg 1.68 months vs Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg 2 months vs Module 11 Cohort C.11.240: AZD6738 240 mg 2.86 months

## Sources

- ClinicalTrials.gov NCT03334617: https://clinicaltrials.gov/study/NCT03334617

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Ceralasertib](https://onco.cc/drugs/ceralasertib/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olaparib](https://onco.cc/drugs/olaparib/), [Oleclumab](https://onco.cc/drugs/oleclumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Vistusertib](https://onco.cc/drugs/vistusertib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- key papers: [Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial](https://onco.cc/key-papers/paper-nct03334617-nat-med-2024/)

---
JSON: https://onco.cc/api/v1/entities/nct03334617.json